Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-767 · 1 trial · 3 indications
Blood samples for pharmacokinetics of ABT-767 will be collected at designated time points
| Arm | Type | Description |
|---|---|---|
| ABT-767 | EXPERIMENTAL | ABT-767 monotherapy |
| Name | Type | Description |
|---|---|---|
| ABT-767 | DRUG | ABT-767 once or twice daily for a 28 day cycle |
Inclusion Criteria: 1. Subject must be ≥ 18 years of age. 2. Subjects must have histological or cytological confirmation of locally advanced or metastatic solid tumor, and a documented Breast Cancer Gene 1 or 2 mutation, or high grade serous ovarian, fallopian tube, or primary peritoneal cancer. 3....
ABT-767 is an investigational small molecule being studied for the treatment of fallopian tube cancer, as well as high grade serous ovarian, primary peritoneal, and solid tumors such as breast, ovarian, prostate, or pancreatic cancer, in patients with BRCA 1 and BRCA 2 mutations.
ABT-767 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV.
ABT-767 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
ABT-767 has been studied in one completed Phase 1 trial, NCT01339650, which enrolled 93 participants with BRCA 1 and BRCA 2 mutations and solid tumors or high grade serous ovarian, fallopian tube, or primary peritoneal cancer. The trial was conducted in the Netherlands.
ABT-767 is the sole name provided for this investigational agent. No alternative names have been reported for this drug.